Why the study?
Does benznidazole improve clinical status and reduce parasitemia in an HIV-infected patient with reactivated Chagas' disease?
Does benznidazole improve clinical status and reduce parasitemia in an HIV-infected patient with reactivated Chagas' disease?
Direct microscopic examination of blood for T. cruzi can be a late finding in Chagas' reactivation in immunocompromised patients, but benznidazole treatment remains effective.
May support benznidazole in HIV-associated Chagas reactivation; hypothesis-generating and challenges direct microscopy as early diagnostic hallmark.
We report a human immunodeficiency virus (HIV)-infected man with chronic Chagas' disease who developed a congestive heart failure that could not be clinically controlled. Endomyocardial biopsy revealed severe myocarditis and the xenodiagnosis result was positive, but Trypanosoma cruzi by direct microscopic examination of the blood was found only four months after the symptoms had started. Treatment with benznidazole was effective in reducing parasitemia, stabilizing the clinical status, and controlling tissue damage related to the parasite. Although the finding of T. cruzi trypomastigotes by direct microscopic examination of the blood has been considered the mark of Chagas' reactivation in immunocompromised patients with chronic disease, in this case it was a late finding.
No takes yet. Share an insight, caveat, or question.
Sartori et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: